Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15100847 | 0.89 | GPR183 (0.53) | GPR183LMNAGAAPKMPOLB | |
| SCHEMBL20408697 | 0.88 | KMT2A (0.57) | LMNAGAAPKMPOLBSMN1; SMN2 | |
| SCHEMBL20408695 | 0.87 | GAA (0.56) | LMNAGAAPKMPOLBSMN1; SMN2 | |
| SCHEMBL18634072 | 0.86 | GPR183 (0.50) | GPR183LMNAGAAPKMPOLB | |
| SCHEMBL20408701 | 0.81 | SMN1; SMN2 (0.62) | LMNAGAAPKMTRPV4HSD11B1 | |
| SCHEMBL20408703 | 0.81 | PKM (0.65) | LMNAGAAPKMSMN1; SMN2MEN1 | |
| SCHEMBL29060791 | 0.80 | TGM2 (0.64) | GPR183LMNAGAAPKMPOLB | |
| SCHEMBL752819 | 0.80 | PKM (0.62) | GPR183LMNAGAAPKMPOLB | |
| SCHEMBL20408699 | 0.79 | LMNA (0.46) | LMNAGAAPKMSMN1; SMN2MEN1 | |
| SCHEMBL15100843 | 0.77 | KMT2A (0.55) | LMNAGAAPKMPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208568-A1 | CARBAMATE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABHD6, ABHD16A, NCEH1 | GPR183 2540/4885LMNA 4712/4885GAA 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.